Successful treatment of relapsed idiopathic multicentric Castleman disease–idiopathic plasmacytic lymphadenopathy with orelabrutinib monotherapy: A case report

British Journal of HaematologyEarly View LETTER TO THE EDITOR Successful treatment of relapsed idiopathic multicentric Castleman disease–idiopathic plasmacytic lymphadenopathy with orelabrutinib monotherapy: A case report Yu-han Gao, Yu-han Gao orcid.org/0000-0002-7249-2855 Department of Haematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaSearch for more papers by this authorMing-hui Duan, Ming-hui Duan orcid.org/0000-0003-2130-6300 Department of Haematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaSearch for more papers by this authorJian Li, Jian Li orcid.org/0000-0002-4549-0694 Department of Haematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaSearch for more papers by this authorLu Zhang, Corresponding Author Lu Zhang [email protected] orcid.org/0000-0002-0860-9625 Department of Haematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China Correspondence Lu Zhang, Department of Haematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. Email: [email protected]Search for more papers by this author Yu-han Gao, Yu-han Gao orcid.org/0000-0002-7249-2855 Department of Haematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaSearch for more papers by this authorMing-hui Duan, Ming-hui Duan orcid.org/0000-0003-2130-6300 Department of Haematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaSearch for more papers by this authorJian Li, Jian Li orcid.org/0000-0002-4549-0694 Department of Haematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaSearch for more papers by this authorLu Zhang, Corresponding Author Lu Zhang [email protected] orcid.org/0000-0002-0860-9625 Department of Haematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China Correspondence Lu Zhang, Department of Haematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. Email: [email protected]Search for more papers by this author First published: 10 June 2024 https://doi.org/10.1111/bjh.19596Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat REFERENCES 1Fajgenbaum DC, Uldrick TS, Bagg A, Frank D, Wu D, Srkalovic G, et al. International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. Blood. 2017; 129(12): 1646–1657. 10.1182/blood-2016-10-746933 CASPubMedWeb of Science®Google Scholar 2Fajgenbaum DC, Langan RA, Japp AS, Partridge HL, Pierson SK, Singh A, et al. Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6-blockade-refractory idiopathic multicentric Castleman disease. J Clin Invest. 2019; 129(10): 4451–4463. 10.1172/JCI126091 PubMedWeb of Science®Google Scholar 3Pierson SK, Katz L, Williams R, Mumau M, Gonzalez M, Guzman S, et al. CXCL13 is a predictive biomarker in idiopathic multicentric Castleman disease. Nat Commun. 2022; 13(1): 7236. 10.1038/s41467-022-34873-7 CASPubMedWeb of Science®Google Scholar 4Pierson SK, Stonestrom AJ, Shilling D, Ruth J, Nabel CS, Singh A, et al. Plasma proteomics identifies a 'chemokine storm' in idiopathic multicentric Castleman disease. Am J Hematol. 2018; 93(7): 902–912. 10.1002/ajh.25123 CASPubMedWeb of Science®Google Scholar 5Gao YH, Liu YT, Zhang MY, Li SY, Fajgenbaum DC, Zhang L, et al. Idiopathic multicentric Castleman disease (iMCD)-idiopathic plasmacytic lymphadenopathy: a distinct subtype of iMCD-not otherwise specified with different clinical features and better survival. Br J Haematol. 2024; 204: 1830–1837. 10.1111/bjh.19334 PubMedWeb of Science®Google Scholar 6Ruth-Anne L, Dustin S, Michael G, Charlly K, Hakon H, Taku K, et al. Single-cell RNA-sequencing of peripheral blood mononuclear cells reveals changes in immune cell composition and distinct inflammatory gene expression profiles during idiopathic multicentric Castleman disease flare. Blood. 2018; 132(Suppl 1): 2406. PubMedGoogle Scholar 7Shi Y, Li J, Zhang L. Daratumumab for the treatment of refractory idiopathic multicentric Castleman disease: a case report. Ann Hematol. 2022; 101(11): 2529–2531. 10.1007/s00277-022-04926-4 PubMedWeb of Science®Google Scholar 8van Rhee F, Voorhees P, Dispenzieri A, Fossa A, Srkalovic G, Ide M, et al. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood. 2018; 132(20): 2115–2124. 10.1182/blood-2018-07-862334 PubMedWeb of Science®Google Scholar 9Pal SS, Dammeijer F, Hendriks RW. Role of Bruton's tyrosine kinase in B cells and malignancies. Mol Cancer. 2018; 17(1): 57. 10.1186/s12943-018-0779-z PubMedGoogle Scholar 10Neys SFH, Hendriks RW, Corneth OBJ. Targeting Bruton's tyrosine kinase in inflammatory and autoimmune pathologies. Front Cell Dev Biol. 2021; 9:668131. 10.3389/fcell.2021.668131 PubMedWeb of Science®Google Scholar 11Zhou J, Zhang L, Liu X, Zhang M, Li J, Zhang W. Evolution of pulmonary involvement in idiopathic multicentric Castleman disease-not otherwise specified: from nodules to cysts or consolidation. Chest. 2023; 164(2): 418–428. 10.1016/j.chest.2023.03.022 PubMedWeb of Science®Google Scholar 12Zhang L, Zhao AL, Duan MH, Li ZY, Cao XX, Feng J, et al. Phase 2 study using oral thalidomide-cyclophosphamide-prednisone for idiopathic multicentric Castleman disease. Blood. 2019; 133(16): 1720–1728. 10.1182/blood-2018-11-884577 CASPubMedWeb of Science®Google Scholar 13Zhang L, Zhang MY, Cao XX, Zhou DB, Fajgenbaum DC, Dong YJ, et al. A prospective, multicenter study of bortezomib, cyclophosphamide, and dexamethasone in relapsed/refractory iMCD. Leuk Lymphoma. 2022; 63(3): 618–626. 10.1080/10428194.2021.1999437 CASPubMedWeb of Science®Google Scholar 14Dhillon S. Orelabrutinib: first approval. Drugs. 2021; 81(4): 503–507. 10.1007/s40265-021-01482-5 CASPubMedWeb of Science®Google Scholar 15Zhang L, Yu-han G, Si-yuan L, Hao Z, Miao-Yan Z, Yan-Ying Y, et al. A prospective study of zanubrutinib, a Bruton tyrosine kinase inhibitor, in relapsed/refractory idiopathic multicentric Castleman disease. Int J Hematol. 2024; 119: 631–637. 10.1007/s12185-024-03747-7 CASPubMedWeb of Science®Google Scholar Early ViewOnline Version of Record before inclusion in an issue ReferencesRelatedInformation